行情

KURA

KURA

Kura Oncology
NASDAQ

实时行情|Nasdaq Last Sale

14.78
-0.07
-0.47%
盘后: 14.78 0 0.00% 16:00 12/13 EST
开盘
14.79
昨收
14.85
最高
15.07
最低
14.54
成交量
41.86万
成交额
--
52周最高
21.42
52周最低
12.30
市值
6.70亿
市盈率(TTM)
-9.6362
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

KURA 新闻

  • 星巴克又"拒服务"美国警察 挨批后道歉、停职员工
  • 海外网.1小时前
  • 英国政府计划脱欧法案 为NHS提供多年资金
  • 新浪财经综合.2小时前
  • 明年2月政府改组 约翰逊或解雇三分之一内阁官员
  • 新浪财经综合.4小时前
  • 结局锁定 特朗普盟友称弹劾案或2020年1月结束进程
  • 中国新闻网.5小时前

更多

所属板块

生物技术和医学研究
+1.07%
制药与医学研究
-0.32%

热门股票

名称
价格
涨跌幅

KURA 简况

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.
展开

Webull提供Kura Oncology Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。